IP Library Granted Patent US 8,447,379
Granted Patent B2
US 8,447,379 · App. 13/249,994 · Granted May 21, 2013

Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof

Inventor: Edward R Flynn (Albuquerque, NM)
Assignee: Senior Scientific, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,447,379
App. No.
13/249,994
Granted
May 21, 2013
Kind
B2
Abstract

The present invention can provide a method of determining the presence, location, quantity, or a combination thereof, of a biological substance, comprising: (a) exposing a sample to a plurality of targeted nanoparticles, where each targeted nanoparticle comprises a paramagnetic nanoparticle conjugated with one or more targeting agents that preferentially bind with the biological substance, under conditions that facilitate binding of the targeting agent to at least one of the one or more biological substances; (b) subjecting the sample to a magnetic field of sufficient strength to induce magnetization of the nanoparticles; (c) measuring a magnetic field of the sample after decreasing the magnetic field applied in step b below a threshold; (d) determining the presence, location, quantity, or a combination thereof, of the one or more biologic substances from the magnetic field measured in step (c).

Claims (26)

1. A method of determining the presence, location, quantity, or a combination thereof, of one or more biological substances, comprising:

(a) exposing a sample to a plurality of targeted nanoparticles, where each targeted nanoparticle comprises a paramagnetic nanoparticle conjugated with one or more targeting agents that preferentially bind with at least one of the biological substances, under conditions that facilitate binding of at least one of the targeting agents to at least one of the one or more biological substances;

(b) subjecting the sample to a magnetic field of sufficient strength to induce magnetization of the nanoparticles;

(c) measuring a magnetic field of the sample after decreasing the magnetic field applied in step b below a threshold;

(d) fitting a decay curve of the magnetic field as measured over a period of time to a log/exponential function to determine the magnetic field of the sample at the time the magnetic field was decreased in step c to determine the presence, location, quantity, or a combination thereof, of the one or more biological substances from the magnetic field measured in step c.

2. A method as in claim 1 , wherein the nanoparticles comprise iron oxide particles having a diameter of about 24 nm, or iron platinum particles having a diameter of about 15 nm.

3. A method as in claim 1 , wherein the magnetic field in step b is applied with sufficient strength and for sufficient time to align the magnetic moments of at least 50% of the nanoparticles.

4. A method as in claim 1 , wherein the magnetic field in step b has a strength of at least 50% of that required to completely saturate the magnetization of the nanoparticles.

5. A method as in claim 1 wherein the magnetic field in step b is applied with sufficient strength and for sufficient time to align the magnetic moments of more than 95% of the nanoparticles.

6. A method as in claim 1 , wherein measuring the magnetic field in step c comprises using one or more superconducting quantum interference devices to measure the magnetic field.

7. A method as in claim 1 , wherein measuring the magnetic field in step c comprises using one or more atomic magnetometers to measure the magnetic field.

8. A method as in claim 1 , wherein measuring the magnetic field in step c comprises using one or more magnetic sensors coupled to one or more second order gradiometers to measure the magnetic field.

9. A method as in claim 1 , wherein measuring the magnetic field in step c comprises using a plurality of magnetic sensors to measure the magnetic field, including measuring spatial characteristics of the magnetic field.

10. A method as in claim 9 , wherein step d comprises determining a spatial distribution of the nanoparticles.

11. A method as in claim 1 , wherein step d comprises solving an inverse electromagnetic problem to determine locations of magnetic sources in the sample.

12. A method as in claim 1 , further comprising repeating steps b through d a plurality of times and averaging the magnetic field measurement in step c, the presence, location, quantity, or a combination thereof, of the one or more biological substances determined in step d, or a combination thereof, of two or more of such repetitions of steps c through d.

13. A method as in claim 1 , wherein measuring the magnetic field in step c comprises measuring the magnetic field over a period of time.

14. An apparatus for the determination of the presence, location, quantity, or a combination thereof, of one or more biological substances, comprising:

a) a magnetization system, configured to subject a sample to a magnetic field, wherein the sample has been exposed to a plurality of targeted nanoparticles, where each targeted nanoparticle comprises a paramagnetic nanoparticle conjugated with one or more targeting agents that preferentially bind with at least one of the biological substances, under conditions that facilitate binding of at least one targeting agent to at least one of the one or more biological substances; wherein the magnetic field has sufficient strength to induce magnetization of the nanoparticles;

b) a magnetic measurement system, configured to measure a magnetic field of the sample after a magnetic field applied by the magnetization system has been decreased below a threshold;

c) an analysis system, configured to fit a decay curve of the magnetic field as measured by the magnetic measurement system over a period of time to a log/exponential function to determine the magnetic field of the sample at the time the magnetic field was decreased to determine the presence, location, quantity, or a combination thereof, of the biologic substance from the magnetic field measured by the magnetic measurement system.

15. An apparatus as in claim 14 , wherein the magnetic measurement system comprises one or more superconducting quantum interference devices.

16. An apparatus as in claim 14 , wherein the magnetic measurement system comprises one or more atomic magnetometers.

17. An apparatus as in claim 14 , wherein the magnetic measurement system comprises one or more magnetic sensors coupled to one or more second order gradiometers.

18. An apparatus as in claim 14 , wherein the magnetic measurement system comprises a plurality of magnetic sensors configured to measure spatial characteristics of the magnetic field, and wherein the analysis system is configured to determine spatial distribution of the nanoparticles from the spatial characteristics of the magnetic field.

19. An apparatus as in claim 14 , wherein the magnetic measurement system is configured to measure the decay of the magnetic field over a period of time.

Assignments (2)
MERGER Recorded Dec 14, 2016
From: SENIOR SCIENTIFIC LLC
To: IMAGION BIOSYSTEMS, INC.
Reel/Frame 040733/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2013
From: FLYNN, EDWARD R
To: SENIOR SCIENTIFIC LLC
Reel/Frame 029976/0712 →
Continuity (23)
Continuation In Part 11940673 · Nov 15, 2007
Continuation In Part 12337554 · Dec 17, 2008
Continuation In Part 11957988 · Dec 17, 2007
Continuation In Part 11940673 · Nov 15, 2007
Continuation In Part 13249994
Continuation In Part PCTUS2010051417 · Oct 5, 2010
Continuation In Part PCTUS2010055729 · Nov 5, 2010
Continuation In Part PCTUS2011028746 · Mar 16, 2011
Provisional Application 61386961 · Sep 27, 2010
Provisional Application 61389233 · Oct 3, 2010
Provisional Application 60866095 · Nov 16, 2006
Provisional Application 61248775 · Oct 5, 2009
Provisional Application 61329076 · Apr 28, 2010
Provisional Application 61377854 · Aug 27, 2010
Provisional Application 61314392 · Mar 16, 2010
Provisional Application 61331816 · May 5, 2010
Provisional Application 61361998 · Jul 7, 2010
Provisional Application 61259011 · Nov 6, 2009
Provisional Application 61308897 · Feb 27, 2010
Provisional Application 61310700 · Mar 4, 2010
Provisional Application 61314370 · Mar 16, 2010
Provisional Application 61454560 · Mar 20, 2011
Related Publication 20120035458A1 · Feb 9, 2012